Diabetic macular edema (DME) occurs as a consequence of diabetes. It typically develops in the advanced stage of diabetic retinopathy and is characterized by leaking fluid from abnormal blood vessels in the eye, which can lead to swelling of the macula and visual impairment. Intravitreal vascular endothelial growth factor (VEGF) inhibitors, such as Regeneron/Bayer HealthCare’s Eylea, Roche/Genentech/Novartis’s Lucentis, and Roche/Genentech’s Avastin, are the most common pharmacotherapies used to treat DME because of their proven efficacy and safety. Allergan’s Ozurdex and Alimera Sciences’ Iluvien, two long-acting corticosteroid implants, are also used to treat DME. However, all of these drugs present clinical shortcomings in efficacy, safety, and/or delivery, creating opportunities for new and improved alternatives. Our content examines the key treatment drivers and analyzes the greatest areas of unmet need and thereby the opportunities in this space.

Questions Answered

  • What are the treatment drivers and goals for DME?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do physicians perceive the current therapies as performing on key treatment drivers and goals for DME?
  • What are the prevailing areas of unmet need and opportunity in DME?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European ophthalmologists for a hypothetical new drug for DME?

Product Description

Unmet Need: Provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 ophthalmologists in the United States and 32 ophthalmologists in Europe

Key companies: Roche/Genentech, Novartis, Regeneron, Bayer HealthCare, Allergan, Alimera Sciences

Key drugs:Lucentis, Eylea, Avastin, Ozurdex, Iluvien, triamcinolone

Key metrics included:

  • Stated versus derived analysis of U.S. and European physicians’ prescribing behavior.
  • Conjoint analysis with U.S. and European physicians, including market simulator.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet need in disease/subpopulation covered and related diseases/subpopulations.
  • Analysis of remaining drug development opportunities.

Table of contents

  • Diabetic Macular Edema / Diabetic Retinopathy - Unmet Need - Detailed, Expanded Analysis: Diabetic Macular Edema (US & EU )

Author(s): Niyati Khetarpal, Ph.D

"Niyati Khetarpal is a business insights analyst on the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope proteins.”


Related Reports

Diabetic Macular Edema / Diabetic Retinopathy - Landscape & Forecast - Disease Landscape & Forecast

Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficit...

View Details

Diabetic Macular Edema / Diabetic Retinopathy - Current Treatment - Detailed, Expanded Analysis (US)

Patients with diabetic retinopathy (DR) experience retinal damage that can lead to vision impairment and eventual blindness, especially with the developmen...

View Details